RemI for Post-Bariatric Surgery Weight Regain
Launched by TEMPLE UNIVERSITY · Feb 27, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called RemI for Post-Bariatric Surgery Weight Regain, is designed to help people who have had weight-loss surgery and are struggling to maintain their weight. Specifically, it focuses on individuals who have gained back more than 5% of their lowest weight after surgery. The trial will compare two different support methods over 12 months: one group will receive a new type of remote therapy that teaches acceptance-based skills to help manage their weight, while the other group will get regular phone calls that remind them of the dietary and behavior changes they learned before their surgery.
To be eligible for this study, participants should be between 18 and 70 years old, have regained at least 5% of their weight, and have undergone certain types of weight-loss surgery (like gastric bypass or sleeve gastrectomy) within the last 6 to 48 months. Those who are pregnant, using weight loss medications, or have certain medical or psychiatric conditions that could interfere with the study are not eligible. Participants can expect to engage in discussions about their eating habits and physical activity, with the goal of understanding how these interventions can help them regain control over their weight and improve their overall health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women
- • Ages 18-70 years old
- • Weight regain of at least 5% from lowest postoperative weight
- • Body mass index (BMI) 25 or above
- • Underwent gastric bypass or sleeve gastrectomy within 6 to 48 months prior to enrollment
- • Ability to give consent
- • Ability to speak, write, and understand English
- Exclusion Criteria:
- • Long-term treatment with oral steroids
- • Current use of weight loss medication (OTC or prescription)
- • Current pregnancy, plan to become pregnant within 12 months, lactation within the past 6 months
- • Psychiatric hospitalization in the past 6 months
- • Documented or self-reported psychiatric diagnosis that would interfere with adherence to the study protocol or acute suicidality
- • Self-report of alcohol or substance abuse within the past 12 months
- • Current, self-reported use of tobacco products
- • Weight loss \> 10 lbs in the past 3 month
- • History of more than one bariatric procedure
- • Inability to walk at least one city block without assistance
About Temple University
Temple University is a leading academic institution located in Philadelphia, Pennsylvania, renowned for its commitment to research and innovation in the health sciences. As a clinical trial sponsor, Temple University leverages its extensive resources, including a diverse pool of participants and cutting-edge facilities, to advance medical knowledge and improve patient care. The university's clinical research initiatives are driven by a multidisciplinary team of experts dedicated to conducting high-quality studies that address critical health issues and contribute to the development of novel therapies. Through its partnerships with local and global organizations, Temple University aims to enhance the translation of research findings into practical applications that benefit communities and advance public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
David B Sarwer, PhD
Principal Investigator
Temple University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported